eBook: Formulation of Dry Powder Inhaler - 17

other mAb treatments. Pulmonary delivery of bevacizumab
and lung cancer treatments, in general, are
a promising development for patients and clinicians,
opening the possibility of maintenance therapy administered
at home with flexible dosing frequencies.
Author Contribution
KBS wrote the manuscript, designed experiments,
and performed spray drying and analytical work.
DTV, JMB, and MB designed the experiments.
PJK designed the in vivo study and wrote the manuscript.
DR and YZ conducted the in vivo study.
MSA performed spray drying.
AP, JCO, LS, and JC performed analytical work.
Funding
This study was funded in its entirety by Lonza.
Declarations
Conflict of Interest The authors declare no competing
interests.
Open Access This article is licensed under a Creative
Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative
Commons licence, and indicate if changes were
made. The images or other third party material in this
article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to
the material. If material is not included in the article's
Creative Commons licence and your intended use is
not permitted by statutory regulation or exceeds the
1. Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery
strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19-40.
https://doi.org/10.1038/nrd.2018.183.
2. Zhong H, Chan G, Hu Y, Hu H, Ouyang D. A comprehensive map
of FDA-approved pharmaceutical products. Pharmaceutics.
2018;10(4). https://doi.org/10.3390/ pharmaceutics10040263.
3. Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferraù F.
Bevacizumab in the treatment of NSCLC: patient selection and
perspectives. Lung Cancer (Auckl). 2017;8:259- 69. https://doi.
org/10.2147/LCTT.S110306.
4. Goel A, Baboota S, Sahni JK, Ali J. Exploring targeted pulmonary
delivery for treatment of lung cancer. Int J Pharm Investig.
2013;3(1):8-14. https://doi.org/10.4103/2230-973X.108959.
5. Paranjpe M, Müller-Goymann CC, et al. Int J Mol Sci. 2014;15(4).
https://doi.org/10.3390/ijms15045852.
6. Cheng H, Zou Y, Shah CD, Fan N, Bhagat TD, Gucalp R, et al. Firstin-human
study of inhaled Azacitidine in patients with advanced
non-small cell lung cancer. Lung Cancer. 2021;154:99- 104.
https://doi.org/10.1016/j.lungcan.2021.02.015.
7. Kuehl PJ, Grimes MJ, Dubose D, Burke M, Revelli DA, Gigliotti AP,
et al. Inhalation delivery of topotecan is superior to intravenous
exposure for suppressing lung cancer in a preclinical model. Drug
Delivery. 2018;25(1):1127-36. https:// doi.org/10.1080/10717544
.2018.1469688.
8. Kuehl PJ, Tellez CS, Grimes MJ, March TH, Tessema M, Revelli DA,
et al. 5-Azacytidine inhaled dry powder formulation profoundly
improves pharmacokinetics and efficacy for lung cancer therapy
through genome reprogramming. Br J Cancer. 2020;122(8):1194-
204. https://doi.org/10.1038/s41416-020-0765-2.
9. McCormack PL, Keam SJ. Bevacizumab. Bevacizumab Drugs.
2008;68(4):487-506. https://doi.org/10.2165/00003495200868040-00009.
permitted
use, you will need to obtain permission
directly from the copyright holder. To view a copy
of this licence, visit http://creativecommons.org/
licenses/by/4.0/.
References
17
http://www.creativecommons.org/ https://www.doi.org/10.1038/nrd.2018.183 https://www.doi.org/10.3390/ https://doi https://www.doi.org/10.4103/2230-973X.108959 https://www.doi.org/10.3390/ijms15045852 https://www.doi.org/10.1016/j.lungcan.2021.02.015 http://https:// http://www.doi.org/10.1080/10717544 https://www.doi.org/10.1038/s41416-020-0765-2 https://www.doi.org/10.2165/00003495

eBook: Formulation of Dry Powder Inhaler

Table of Contents for the Digital Edition of eBook: Formulation of Dry Powder Inhaler

eBook: Formulation of Dry Powder Inhaler - 1
eBook: Formulation of Dry Powder Inhaler - 2
eBook: Formulation of Dry Powder Inhaler - 3
eBook: Formulation of Dry Powder Inhaler - 4
eBook: Formulation of Dry Powder Inhaler - 5
eBook: Formulation of Dry Powder Inhaler - 6
eBook: Formulation of Dry Powder Inhaler - 7
eBook: Formulation of Dry Powder Inhaler - 8
eBook: Formulation of Dry Powder Inhaler - 9
eBook: Formulation of Dry Powder Inhaler - 10
eBook: Formulation of Dry Powder Inhaler - 11
eBook: Formulation of Dry Powder Inhaler - 12
eBook: Formulation of Dry Powder Inhaler - 13
eBook: Formulation of Dry Powder Inhaler - 14
eBook: Formulation of Dry Powder Inhaler - 15
eBook: Formulation of Dry Powder Inhaler - 16
eBook: Formulation of Dry Powder Inhaler - 17
eBook: Formulation of Dry Powder Inhaler - 18
eBook: Formulation of Dry Powder Inhaler - 19
eBook: Formulation of Dry Powder Inhaler - 20
eBook: Formulation of Dry Powder Inhaler - 21
eBook: Formulation of Dry Powder Inhaler - 22
eBook: Formulation of Dry Powder Inhaler - 23
eBook: Formulation of Dry Powder Inhaler - 24
eBook: Formulation of Dry Powder Inhaler - 25
eBook: Formulation of Dry Powder Inhaler - 26
eBook: Formulation of Dry Powder Inhaler - 27
eBook: Formulation of Dry Powder Inhaler - 28
eBook: Formulation of Dry Powder Inhaler - 29
eBook: Formulation of Dry Powder Inhaler - 30
eBook: Formulation of Dry Powder Inhaler - 31
eBook: Formulation of Dry Powder Inhaler - 32
eBook: Formulation of Dry Powder Inhaler - 33
eBook: Formulation of Dry Powder Inhaler - 34
eBook: Formulation of Dry Powder Inhaler - 35
eBook: Formulation of Dry Powder Inhaler - 36
eBook: Formulation of Dry Powder Inhaler - 37
eBook: Formulation of Dry Powder Inhaler - 38
eBook: Formulation of Dry Powder Inhaler - 39
eBook: Formulation of Dry Powder Inhaler - 40
eBook: Formulation of Dry Powder Inhaler - 41
eBook: Formulation of Dry Powder Inhaler - 42
eBook: Formulation of Dry Powder Inhaler - 43
eBook: Formulation of Dry Powder Inhaler - 44
eBook: Formulation of Dry Powder Inhaler - 45
eBook: Formulation of Dry Powder Inhaler - 46
eBook: Formulation of Dry Powder Inhaler - 47
https://www.nxtbookmedia.com